CPC C07K 16/28 (2013.01) [A61K 31/4745 (2013.01); A61K 39/001102 (2018.08); A61K 39/39558 (2013.01); C07K 14/51 (2013.01); C07K 16/18 (2013.01); C07K 16/3046 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); G01N 33/57419 (2013.01); G01N 33/57492 (2013.01); A61K 2039/55566 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/726 (2013.01); G01N 2800/52 (2013.01)] | 17 Claims |
1. A method for detecting a cancer stem cell (CSC) in a sample, comprising:
contacting the sample with at least one antibody that binds an ectodysplasin A receptor (EDAR) protein of SEQ ID NO: 1, a CD70 protein of SEQ ID NO: 2, an epiregulin (EREG) protein of SEQ ID NO: 3, a protein C receptor, endothelial (PROCR) protein of SEQ ID NO: 5, a prominin 2 (PROM2) protein of SEQ ID NO: 6, a tumor necrosis factor (ligand) superfamily, member 9 (TNFSF9) protein of SEQ ID NO: 7, a poliovirus receptor-related 4 (PVRL4) protein of SEQ ID NO: 8, or a TNF receptor superfamily, member 6 (FAS) protein of SEQ ID NO: 9; and
detecting binding of the at least one antibody to the sample, thereby detecting the CSC,
wherein the sample is from a patient with cancer, and the cancer is an Lgr5-negative cancer.
|